Flashy lungs and sarcoidosis: not always a sign of disease activity.

Sarcoidosis Vasc Diffuse Lung Dis

Institut de Cardiologie de Montréal.

Published: March 2024

AI Article Synopsis

  • A 68-year-old man who has a heart condition called cardiac sarcoidosis was getting treated with a medicine called methotrexate.
  • He started having trouble breathing and felt dizzy, so doctors ran some tests.
  • The tests showed that the medicine was causing problems in his lungs, but this got better when they stopped the methotrexate. This is the first time they found this kind of lung reaction using a special scan called FDG-PET/CT.

Article Abstract

This is the case of a 68-year-old man with known cardiac sarcoidosis undergoing treatment with methotrexate who presented with new onset of dyspnea and lipothymia. FDG-PET/CT revealed pathological uptake within lung parenchyma which resolved following discontinuation of methotrexate, compatible with methotrexate-induced pneumonitis. This is the first case of methotrexate-induced pneumonitis documented by FDG-PET/CT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008334PMC
http://dx.doi.org/10.36141/svdld.v41i1.14626DOI Listing

Publication Analysis

Top Keywords

methotrexate-induced pneumonitis
8
flashy lungs
4
lungs sarcoidosis
4
sarcoidosis sign
4
sign disease
4
disease activity
4
activity case
4
case 68-year-old
4
68-year-old man
4
man cardiac
4

Similar Publications

Article Synopsis
  • - Varicella-zoster virus causes chicken pox and shingles, and while usually mild in kids, it can be serious in immunocompromised individuals.
  • - An 11-year-old boy on methotrexate (not typically immunosuppressive) developed a severe varicella infection that led to pneumonia.
  • - He was treated with high-dose acyclovir and intravenous immunoglobulin (IVIG), which helped him recover completely thanks to their effectiveness in immunocompromised patients.
View Article and Find Full Text PDF

Methotrexate (MTX), a cornerstone treatment for rheumatoid arthritis (RA), is associated with drug-induced hypersensitivity syndrome (DIHS), including rare instances of methotrexate-induced pneumonitis. We report a significant case of a 65-year-old woman with RA, treated with MTX for over two decades, who presented with fever, headache, nausea, and malaise and was later diagnosed with DIHS, manifesting as pneumonitis and hepatosplenomegaly. Despite initial suspicion of bacterial pneumonia, her condition deteriorated, leading to the consideration of DIHS.

View Article and Find Full Text PDF
Article Synopsis
  • A 68-year-old man who has a heart condition called cardiac sarcoidosis was getting treated with a medicine called methotrexate.
  • He started having trouble breathing and felt dizzy, so doctors ran some tests.
  • The tests showed that the medicine was causing problems in his lungs, but this got better when they stopped the methotrexate. This is the first time they found this kind of lung reaction using a special scan called FDG-PET/CT.
View Article and Find Full Text PDF

Dihydromyricetin Modulates Nrf2 and NF-κB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity.

Pharmaceuticals (Basel)

March 2023

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia 61511, Egypt.

Background: Methotrexate (MTX) is an effective anticancer, anti-inflammatory, and immunomodulatory agent. However, it induces a serious pneumonitis that leads to irreversible fibrotic lung damage. This study addresses the protective role of the natural flavonoid dihydromyricetin (DHM) against MTX-induced pneumonitis via modulation of Nrf2/NF-κB signaling crosstalk.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!